Cargando…
A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation
The oncofetal mRNA-binding protein, IMP1 or insulin-like growth factor-2 mRNA-binding protein 2 (IGF2BP1), binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, leading to increased expression of the proteins encoded by its target mRNAs. IMP1 is frequently overexpressed in cancer and is...
Autores principales: | Mahapatra, Lily, Andruska, Neal, Mao, Chengjian, Le, Jeremy, Shapiro, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576976/ https://www.ncbi.nlm.nih.gov/pubmed/28846937 http://dx.doi.org/10.1016/j.tranon.2017.07.008 |
Ejemplares similares
-
BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells
por: Jamal, Alam, et al.
Publicado: (2023) -
A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
por: Němejcová, Kristýna, et al.
Publicado: (2023) -
Anticipatory Estrogen Activation of the Unfolded Protein Response is Linked to Cell Proliferation and Poor Survival in Estrogen Receptor α Positive Breast Cancer
por: Andruska, Neal, et al.
Publicado: (2014) -
Feasibility of IMP-3 as an Invasiveness Marker for Acral Lentiginous Melanoma
por: Seo, Jeong-Wan, et al.
Publicado: (2018) -
Mitogen-activated protein kinase inhibitors reduce the nuclear accumulation of phosphorylated Smads by inhibiting Imp 7 or Imp 8 in HepG2 cells
por: Hu, Xiangpeng, et al.
Publicado: (2018)